Published in Gut on December 01, 1973
Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ (1989) 4.13
An oral preparation to release drugs in the human colon. Br J Clin Pharmacol (1982) 3.49
Sulphasalazine desensitisation. Br Med J (Clin Res Ed) (1981) 2.94
Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis. Gut (1980) 2.81
Microscopic activity in ulcerative colitis: what does it mean? Gut (1991) 2.43
Azathioprine in ulcerative colitis: final report on controlled therapeutic trial. Br Med J (1974) 2.24
Distribution and metabolism in healthy volunteers of disodium azodisalicylate, a potential therapeutic agent for ulcerative colitis. Gut (1982) 1.60
Incidence of sulphasalazine-induced male infertility. Gut (1981) 1.58
Olsalazine in active ulcerative colitis. Br Med J (Clin Res Ed) (1985) 1.55
Effects of sulphasalazine (Salazopyrin) on faecal flora in patients with inflammatory bowel disease. Gut (1974) 1.47
What dose of 5-aminosalicylic acid (mesalazine) in ulcerative colitis? Gut (1998) 1.43
Influence of intestinal transit time on azo-reduction of salicylazosulphapyridine (Salazopyrin). Gut (1979) 1.43
Effects of olsalazine and sulphasalazine on jejunal and ileal water and electrolyte absorption in normal human subjects. Gut (1991) 1.40
Inhibition of leucocyte motility by drugs used in ulcerative colitis. Gut (1981) 1.23
Effect of azodisal sodium and sulphasalazine on ileostomy output of fluid and PGE2 and PGF2 alpha in subjects with a permanent ileostomy. Gut (1986) 1.20
Comparative trial of sulphasalazine and oral sodium cromoglycate in the maintenance of remission in ulcerative colitis. Gut (1978) 1.19
Rheumatic manifestations of inflammatory bowel disease. World J Gastroenterol (2009) 1.16
Azo reduction of sulphasalazine in healthy volunteers. Br J Clin Pharmacol (1982) 1.15
Red cell abnormalities associated with sulphasalazine maintenance therapy for ulcerative colitis. Gut (1975) 1.15
Renal tubular dysfunction in patients with inflammatory bowel disease treated with aminosalicylate. Gut (1997) 1.08
Pharmacological and biochemical actions of sulphasalazine. Drugs (1986) 1.05
Controlled trial comparing olsalazine and sulphasalazine for the maintenance treatment of ulcerative colitis. Gut (1988) 1.02
The value of 5-aminosalicylic acid in inflammatory bowel disease for patients intolerant or allergic to sulphasalazine. Postgrad Med J (1985) 1.02
Sulphasalazine: a review of 40 years' experience. Drugs (1986) 1.01
Tests of renal function in patients with quiescent colitis: effects of drug treatment. Gut (1992) 0.95
The effect of the acetylator phenotype on the metabolism of sulphasalazine in man. J Med Genet (1983) 0.94
Sulphasalazine induced seminal abnormalities in ulcerative colitis: results of mesalazine substitution. Gut (1987) 0.91
Sulphasalazine in asymptomatic Crohn's disease. A multicentre trial. Gut (1977) 0.91
Maintenance of remission in ulcerative colitis with sulphasalazine or a high-fibre diet: a clinical trial. Br Med J (1978) 0.91
Enteropathic spondyloarthritis: from diagnosis to treatment. Clin Dev Immunol (2013) 0.87
Meta-analysis of the placebo response in ulcerative colitis. Dig Dis Sci (2007) 0.86
Medical treatment of ulcerative colitis. Clin Colon Rectal Surg (2004) 0.86
Release of 5-aminosalicylic acid from Pentasa during normal and accelerated intestinal transit time. Br J Clin Pharmacol (1987) 0.85
A double-blind controlled trial of the effect of sodium cromoglycate in preventing relapse in ulcerative colitis. Postgrad Med J (1981) 0.84
Medical treatment of ulcerative colitis. Postgrad Med J (1984) 0.83
Actions of anticolitic drugs on a guinea-pig model of immune colitis. Agents Actions (1982) 0.82
Role of tyrosine 131 in the active site of paAzoR1, an azoreductase with specificity for the inflammatory bowel disease prodrug balsalazide. Acta Crystallogr Sect F Struct Biol Cryst Commun (2009) 0.82
Ulcerative colitis: current treatment strategies and future prospects. Therap Adv Gastroenterol (2009) 0.81
Longterm olsalazine treatment: pharmacokinetics, tolerance and effects on local eicosanoid formation in ulcerative colitis and Crohn's colitis. Gut (1988) 0.81
Optimal Endpoint of Therapy in IBD: An Update on Factors Determining a Successful Drug Withdrawal. Gastroenterol Res Pract (2015) 0.79
Exacerbation of bloody diarrhea as a side effect of mesalamine treatment of active ulcerative colitis. Case Rep Gastroenterol (2011) 0.79
Management of arthropathy in inflammatory bowel diseases. Ther Adv Chronic Dis (2015) 0.77
Advances in refractory ulcerative colitis treatment: A new therapeutic target, Annexin A2. World J Gastroenterol (2015) 0.77
Comparison of the single dose pharmacokinetics of sulphasalazine in rheumatoid arthritis and inflammatory bowel disease. Ann Rheum Dis (1990) 0.76
Duration of treatment with 5-aminosalicylic acid compounds. World J Gastroenterol (2007) 0.76
Diagnosis and management of inflammatory bowel disease. Can Fam Physician (1976) 0.76
Liver and gastrointestinal function in pregnancy. Postgrad Med J (1979) 0.76
Treatment of ulcerative colitis. Br Med J (Clin Res Ed) (1981) 0.75
Some aspects of medical management of gastrointestinal disease. Part II. Can Med Assoc J (1975) 0.75
Ulcerative colitis flair induced by mesalamine suppositories hypersensitivity. World J Gastroenterol (2014) 0.75
Inflammatory bowel disease. CMAJ (1989) 0.75
Medical treatment of ulcerative colitis: scoring the advances. Gut (1988) 0.75
Editorial: Sulphasalazine for Crohn's diseases? Br Med J (1975) 0.75
Sulphasalazine and salicylazosulphadimidine in ulcerative colitis. Lancet (1962) 7.75
An assessment of prednisone, salazopyrin, and topical hydrocortisone hemisuccinate used as out-patient treatment for ulcerative colitis. Gut (1960) 4.23
Comparison of corticosteroid and sulphasalazine therapy in ulcerative colitis. Br Med J (1962) 3.95
PREDNISONE AS MAINTENANCE TREATMENT FOR ULCERATIVE COLITIS IN REMISSION. Lancet (1965) 3.92
Cortisone and corticotrophin in ulcerative colitis. Br Med J (1959) 3.69
The prophylactic effect of salazosulphapyridine in ulcerative colitis during long-term treatment. A double-blind trial on patients asymptomatic for one year. Scand J Gastroenterol (1973) 1.82
An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet (1977) 7.89
The histological diagnosis of chronic gastritis in fibreoptic gastroscope biopsy specimens. J Clin Pathol (1972) 6.07
Haematemesis and melaena, with special reference to factors influencing the outcome. Br Med J (1970) 4.31
Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet (1974) 4.06
Colorectal cancer in ulcerative colitis: a cohort study of primary referrals from three centres. Gut (1988) 3.66
Treatment of irritable bowel syndrome with lorazepam, hyoscine butylbromide, and ispaghula husk. Br Med J (1979) 3.56
Transit times of food in patients with diverticulosis or irritable colon syndrome and normal subjects. Br Med J (1967) 3.51
Prevalence of colonic diverticulosis in general population of Oxford area. Br Med J (1967) 3.44
Course and prognosis of Crohn's disease. Gut (1976) 3.02
Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis. Gut (1980) 2.81
Gastric ulcer and gastritis. Gut (1971) 2.58
Gastric cancer simulating benign gastric ulcer. Br J Surg (1969) 2.27
Auto-immune reactions in ulcerative colitis. Gut (1966) 2.26
Further experience in the treatment of severe attacks of ulcerative colitis. Lancet (1978) 2.25
Azathioprine in ulcerative colitis: final report on controlled therapeutic trial. Br Med J (1974) 2.24
Method of preparing isolated colonic epithelial cells (colonocytes) for metabolic studies. Gut (1979) 2.08
Jejunal mucosal recovery in coeliac disease in relation to the degree of adherence to a gluten-free diet. Q J Med (1974) 1.95
Ulcerative colitis and pregnancy. Gut (1980) 1.90
The histological classification of duodenitis in fibreoptic biopsy specimens. Digestion (1975) 1.89
Crohn's disease and carcinoma of colon. Br Med J (1968) 1.77
Abnormalities in the apparently normal bowel mucosa in Crohn's disease. Lancet (1976) 1.77
Distribution and metabolism in healthy volunteers of disodium azodisalicylate, a potential therapeutic agent for ulcerative colitis. Gut (1982) 1.60
Gastroscopy with biopsy and cytological sampling under direct vision. Br Med J (1968) 1.53
Disaccharidase activity and jejunal morphology in coeliac disease. Q J Med (1972) 1.48
The effect of topical N-acetyl-5-aminosalicylic acid in ulcerative colitis. Scand J Gastroenterol (1980) 1.46
Hypolactasia and the irritable colon syndrome. Scand J Gastroenterol (1972) 1.42
Comparison of disodium cromoglycate and sulphasalazine as maintenance therapy for ulcerative colitis. Lancet (1979) 1.40
The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man. Br J Clin Pharmacol (1982) 1.40
Immunosuppression in the treatment of inflammatory bowel disease. I. Changes in lymphoid sub-populations in the blood and rectal mucosa following cessation of treatment with azathioprine. Clin Exp Immunol (1974) 1.39
Circulating and tissue eosinophils in ulcerative colitis. Am J Dig Dis (1966) 1.32
Lack of harmful effect of oats on small-intestinal mucosa in coeliac disease. Br Med J (1974) 1.31
Stimulation of lymphocytes from patients with coeliac disease by a subfraction of gluten. Lancet (1976) 1.31
Propulsion and retropulsion of normal colonic contents. Am J Dig Dis (1971) 1.30
The timing of histological damage following a single challenge with gluten in treated coeliac disease. Q J Med (1981) 1.29
Azathioprine in ulcerative colitis: an interim report on a controlled therapeutic trial. Br Med J (1972) 1.28
The liver in ulcerative colitis. Q J Med (1971) 1.27
Glucosamine synthetase activity of the colonic mucosa in ulcerative colitis and Crohn's disease. Gut (1977) 1.26
Gastritis duodenitis, and circulating levels of gastrin in duodenal ulcer before and after vagotomy. Gut (1976) 1.25
Cerebral venous thrombosis as a complication of ulcerative colitis. Am J Dig Dis (1967) 1.25
Comparison of various treatments for irritable bowel syndrome. Br Med J (1980) 1.20
The role of various cereals in coeliac disease. Q J Med (1978) 1.19
The liver in Crohn's disease. Q J Med (1971) 1.16
Circulating antibodies to cow's milk proteins in ulcerative colitis. Gut (1972) 1.16
Identifying toxic fractions of wheat gluten and their effect on the jejunal mucosa in coeliac disease. Gut (1974) 1.13
Proctocolectomy for ulcerative colitis. World J Surg (1980) 1.12
Campylobacter colitis. J Clin Pathol (1979) 1.12
Intensive intravenous regimen for membranous colitis. Br Med J (1976) 1.11
Tissue eosinophils in ulcerative colitis. Scand J Gastroenterol (1979) 1.10
English proficiency in multiple-choice questions. Acad Med (1990) 1.08
The management of ulcerative colitis. Br J Clin Pract (1974) 1.07
Split ileostomy and ileocolostomy for Crohn's disease of the colon and ulcerative colitis: a 20 year survey. Gut (1983) 1.06
Circulating levels of sulphasalazine and its metabolites and their relation to the clinical efficacy of the drug in ulcerative colitis. Gut (1980) 1.06
Luminal ions and short chain fatty acids as markers of functional activity of the mucosa in ulcerative colitis. J Clin Pathol (1982) 1.05
Water and electrolyte balance in subjects with a permanent ileostomy. Gut (1983) 1.05
Placental and mammary transfer of sulphasalazine. Br Med J (1979) 1.04
The effects of prednisolone in leucocyte function in man. A double blind controlled study. Clin Exp Immunol (1977) 1.04
Movements of the large intestine. Physiol Rev (1966) 1.04
The health of subjects living with a permanent ileostomy. Q J Med (1982) 1.04
Skin test for coeliac disease using a subfraction of gluten. Lancet (1977) 1.04
Segmentation and the localization of intraluminal pressure in the human colon, with special reference to the pathogenesis of colonic diverticula. Gastroenterology (1968) 1.01
Breakfast and Crohn's disease--I. Br Med J (1978) 1.00
Immunosuppression in the treatment of inflammatory bowel disease. II. The effects of azathioprine on lymphoid cell populations in a double blind trial in ulcerative colitis. Clin Exp Immunol (1976) 0.96
The effect of the acetylator phenotype on the metabolism of sulphasalazine in man. J Med Genet (1983) 0.94
Circulating immune complexes in ulcerative colitis and Crohn's disease. Gut (1972) 0.94
Pericarditis associated with ulcerative colitis and Crohn's disease. Am J Dig Dis (1976) 0.92
Medical management of ulcerative colitis. Br Med J (1968) 0.91
Haustral movement in the human colon. Gut (1969) 0.90
Reaginic hypersensitivity in ulcerative colitis. Gut (1972) 0.90
Blood Groups and Secretor Status in Ulcerative Colitis. Br Med J (1961) 0.89
Disodium azodisalicylate in ulcerative colitis. Lancet (1981) 0.87
The thyroid in ulverative colitis and Crohn's disease. II. Thyroid enlargement and hyperthyroidism in ulcerative colitis. Acta Med Scand (1975) 0.87
Coconut fats. Ceylon Med J (2006) 0.84
Human colonic motility. A comparative study of normal subjects, patients with ulcerative colitis, and patients with the irritable colon syndrome. Gastroenterology (1968) 0.83
Propulsion and retropulsion in the human colon demonstrated by time-lapse cinefluorography. Gut (1968) 0.83
Hookworm infection in Great Britain: experimental observations. Br Med J (1965) 0.83
Gut hormone responses in subjects with a permanent ileostomy. Digestion (1982) 0.82
Effects of carbohydrate meals of varying consistency on gastric myoelectrical activity. Singapore Med J (2002) 0.82
Observations on experimentally induced colonic pain. Gut (1972) 0.82
Medical management of ulcerative colitis and indications for colectomy. World J Surg (1988) 0.81
Small intestinal mucosal abnormalities and disaccharidase activity in pernicious anaemia. Br J Haematol (1972) 0.81
Regional enteritis and glucose-6-phosphate dehydrogenase deficiency. N Engl J Med (1969) 0.81
Morphology and disaccharidase levels of jejunal biopsy specimens from healt by british subjects. Digestion (1973) 0.81
Audit of asthma management in private general practice in Oman. Ann Saudi Med (1997) 0.80
Urinary stones in subjects with a permanent ileostomy. Br J Surg (1982) 0.80
Hypolactasia and the irritable colon syndrome. Gut (1969) 0.79
Ulcerative colitis beginning in childhood. N Engl J Med (1971) 0.79
Proceedings: The histological state of the gastric and duodenal mucosa in healthy volunteers. Gut (1975) 0.79
The thyroid in ulcerative colitis and Crohn's disease. V. Triiodothyronine. Effect of corticosteroids and influence of severe disease. Acta Med Scand (1976) 0.78
A therapeutic trial of anti-lymphocytic globulin in acute ulcerative colitis. Digestion (1980) 0.78
Calcium metabolism in subjects living with a permanent ileostomy. Digestion (1983) 0.77
Treatment of chronic gastric ulcer with gefarnate: a long-term controlled therapeutic trial. Curr Med Res Opin (1976) 0.77
Ulcerative colitis. Medical management. Br Med J (1971) 0.77
Problems associated with the use of merthiolate as a preservative in anti-lymphocytic globulin. Toxicology (1979) 0.77
Glucosamine synthetase activity of the colonic mucosa in membranous colitis. Gut (1977) 0.77
Intrinsic factor secretion after vagotomy. Br J Surg (1977) 0.77
The thyroid in ulcerative colitis and Crohn's disease. IV. Thyroid hormone binding proteins. Acta Med Scand (1975) 0.77